文献速递心境障碍会诊联络精神医学

冰岛接受锂盐治疗个体慢性肾脏病风险:全国性回顾性队列研究

Risk of chronic kidney disease in individuals on lithium therapy in Iceland: a nationwide retrospective cohort study.
PubMed 文献 · Lancet Psychiatry · 2024-01-01

该研究为冰岛全国性回顾性队列研究,纳入2008至2017年接受锂盐治疗的心境障碍成人及未用锂盐的对照,发现锂盐组3期及以上慢性肾脏病风险高于对照组(HR 1.90,95%CI 1.32-2.75),且风险随血锂浓度升高而增加。

要点

  • 锂盐组3期及以上慢性肾脏病发生率为10.4%,对照组为3.0%,校正后HR 1.90(95%CI 1.32-2.75)。
  • 平均血锂0.60-0.79 mmol/L组HR 2.93(95%CI 1.97-4.36),0.80-0.99 mmol/L组HR 4.31(95%CI 2.66-6.99)。
  • 平均血锂0.30-0.59 mmol/L组HR 1.22(95%CI 0.78-1.90),未达统计学显著。

核心结论

  • 接受锂盐治疗的心境障碍个体发生3期及以上慢性肾脏病的风险增加,且呈血药浓度依赖性。
  • 年龄、初始eGFR、糖尿病和急性肾损伤史也是3期及以上慢性肾脏病的显著危险因素。
  • 作者建议在考虑其他危险因素的同时,仔细监测血锂浓度并使用最低有效锂剂量以帮助降低慢性肾脏病风险。

研究设计与样本

  • 冰岛全国性回顾性人群队列研究,纳入2008至2017年接受锂盐治疗且至少两次血清肌酐检测的≥18岁心境障碍成人。
  • 排除2008年1月1日前已有慢性肾脏病(ICD编码或eGFR<60 mL/min per 1.73 m2)或诊断有肾小球疾病、遗传或先天性肾脏病、小肾脏者。
  • 采用时间至事件回归分析评估2008年1月1日至2017年12月31日发生3期及以上慢性肾脏病的风险,并考虑死亡竞争风险。
  • 共识别4310人(锂盐组2695人,对照组1615人),最终纳入分析3198人。

主要发现

  • 随访结束时纳入锂盐组2025人(75.1%;女性1165人[57.5%],男性860人[42.5%])和对照组1173人(72.6%;女性737人[62.8%],男性436人[37.2%])。
  • 研究样本随访结束时平均年龄46.6岁(SD 16.4;范围18.5-98.9)。
  • 锂盐组2025人中211人(10.4%)发生3期及以上慢性肾脏病,对照组1173人中35人(3.0%)发生,校正性别、年龄和共病后HR 1.90(95%CI 1.32-2.75)。
  • 与对照组相比,平均血锂浓度0.60-0.79 mmol/L亚组HR 2.93(95%CI 1.97-4.36),0.80-0.99 mmol/L亚组HR 4.31(95%CI 2.66-6.99),均显著增加。
  • 平均血锂浓度0.30-0.59 mmol/L亚组HR 1.22(95%CI 0.78-1.90),未达统计学显著。

关键数值与推荐

  • 3期及以上慢性肾脏病依据2012年肾脏病改善全球结局(KDIGO)慢性肾脏病评估与管理临床实践指南定义。
  • eGFR由血清肌酐计算;ICD-10和ICD-9诊断编码、血清肌酐、血锂浓度及尿白蛋白肌酐比来自医疗机构和实验室。

临床怎么用

  • 作者建议在考虑其他危险因素(如年龄或临床共病)的同时,仔细监测血锂浓度并使用最低有效锂剂量以达到充分心境稳定,以帮助降低慢性肾脏病风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between lithium use and chronic kidney disease, and the effect of comorbidities on this association are poorly understood. Our aim was to examine the risk of developing stage 3 or higher chronic kidney disease among people receiving lithium therapy. METHODS: This was a retrospective, population-based cohort study of all adults (aged ≥18 years) in Iceland treated with lithium for a mood disorder who had two or more serum creatinine measurements available in the years 2008-17, irrespective of duration of lithium therapy, identified from the Prescription Medicines Register of the Directorate of Health, or through blood lithium measurements. The control group comprised all eligible outpatients with mood disorders (ICD-10 codes F30-F39) who had not been prescribed lithium and who had attended the national tertiary referral centre in 2014-16. Individuals with chronic kidney disease (identified by ICD codes or an estimated glomerular filtration rate [eGFR] <60 mL/min per 1·73 m2) before Jan 1, 2008, or those with glomerular disease, genetic or congenital kidney disease, or small kidneys diagnosed before or after 2008 were excluded. Chronic kidney disease stages 3 and higher were defined according to the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, and the eGFR was calculated from serum creatinine; all ICD-10 and ICD-9 diagnosis codes, serum creatinine and blood lithium concentrations, and urine albumin-to-creatinine ratios were obtained from health-care institutions and laboratories. Risk of developing stage 3 or higher chronic kidney disease between Jan 1, 2008, and Dec 31, 2017, was assessed using time-to-event regression analysis, accounting for competing risk of death. People with lived experience were not involved in the design or conduct of this study. FINDINGS: We identified 4310 individuals (2695 who had received lithium and 1615 control participants), of whom 3198 were included in the study. 2025 (75·1%) individuals in the lithium group (1165 [57·5%] female and 860 [42·5%] male) and 1173 (72·6%) in the control group (737 [62·8%] female and 436 [37·2%] male) were included in the study at end of follow-up. The mean age of the study sample at the end of follow-up was 46·6 years (SD 16·4; range 18·5-98·9). Ethnicity data were not available. In the lithium group, 211 (10·4%) of 2025 individuals developed stage 3 or higher chronic kidney disease, compared with 35 (3·0%) of 1173 individuals in the control group (hazard ratio [HR] 1·90, 95% CI 1·32-2·75 after adjusting for sex, age, and comorbid conditions). Compared with control participants, the risk of stage 3 or higher chronic kidney disease was significantly increased for subgroups with a mean blood lithium concentration of 0·60-0·79 mmol/L (HR 2·93, 95% CI 1·97-4·36) or 0·80-0·99 mmol/L (4·31, 2·66-6·99), but not for the subgroup with a mean blood lithium concentration of 0·30-0·59 mmol/L (1·22, 0·78-1·90). Analyses also showed that age, initial eGFR, diabetes, and history of acute kidney injury were significant risk factors for developing stage 3 or higher chronic kidney disease. INTERPRETATION: Individuals with mood disorders receiving lithium treatment had an increased risk of developing stage 3 or higher chronic kidney disease in a blood concentration-dependent manner. We also found that other factors, including age, initial eGFR, and comorbidities were associated with increased risk of for developing stage 3 or higher chronic kidney disease. Overall, our findings suggest that in addition to considering other risk factors (eg, age or clinical comorbidities), careful monitoring of blood lithium concentrations and use of the lowest effective lithium dose for adequate mood stabilisation is recommended for helping to mitigate the risk of chronic kidney disease. FUNDING: Akureyri Hospital Research Fund and Landspitali University Hospital Science Fund.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gislason G, Indridason OS, Sigurdsson E, et al. Risk of chronic kidney disease in individuals on lithium therapy in Iceland: a nationwide retrospective cohort study. Lancet Psychiatry. 2024. PMID: 39572104. doi:10.1016/S2215-0366(24)00324-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。